Related Experiment Video
Updated: Aug 5, 2026

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
Potential Clinical Impact of Revised Pulmonary Hypertension Definitions at Moderate Altitude
August Longino1, Alexandra N Fuher1, Kaitlyn Mcleod1
1Department of Internal Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Revised pulmonary hypertension (PH) definitions identify patients with higher mortality risk at moderate altitudes. The updated 2022 precapillary PH criteria capture a distinct population with lower mortality and less disease progression.
Area of Science:
- Cardiology
- Pulmonology
- Medical Diagnostics
Background:
- Pulmonary hypertension (PH) and precapillary PH definitions were revised in 2018 and 2022.
- Previous definitions used a mean pulmonary arterial pressure (mPAP) ≥ 25 mm Hg and pulmonary vascular resistance (PVR) ≥ 3 Wood units.
- Revised definitions lowered the mPAP threshold to 20 mm Hg and PVR to > 2 Wood units.
Purpose of the Study:
- To evaluate the impact of revised PH and precapillary PH definitions at moderate altitude.
- To determine if revised definitions capture similar patient populations at altitude compared to sea level.
- To assess the prognostic implications of these revised definitions on patient mortality and disease progression.
Main Methods:
- Analysis of hemodynamic data from right heart catheterization procedures in 2,382 patients residing at 1,609 m.
- Extraction of clinical data on PH diagnosis, progression, and mortality from electronic medical records and the National Death Index.
- Comparison of patient cohorts and mortality outcomes based on pre-2018, post-2018, and post-2022 diagnostic criteria.
Main Results:
- Applying the post-2018 definition significantly reduced the prevalence of PH diagnoses compared to pre-2018 criteria (59.2% vs. 12.8%).
- The post-2022 definition increased the prevalence of precapillary PH diagnoses (P < .05).
- Patients diagnosed with PH under revised criteria exhibited lower mortality than pre-2018 PH patients but higher than those without PH. Post-2022 precapillary PH patients showed lower mortality compared to pre-2018 precapillary PH patients.
Conclusions:
- Revised PH definitions at moderate altitude identify patients with mortality risks comparable to sea-level findings.
- The post-2022 precapillary PH definition identifies a population with lower mortality and no significant disease progression.
- Further research is warranted to understand the clinical implications and management of this newly identified precapillary PH population at altitude.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
